Trial Profile
Clinical and Immune-Modulating Effects of CC-10004 [apremilast] in Discoid Lupus Erythematosus.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Discoid lupus erythematosus
- Focus Therapeutic Use
- 03 Jan 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 03 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2008 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.